David Posnick, DO
Dermatology · Nashua, NHNPI 1629333182
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $127,317 of the $203,143 with a category attached, or 62.7%. 36 manufacturers reported payments, led by Galderma Laboratories, L.p. at 45.3% of the total. 2025 is the largest year on record at $113,253, more than ten times the $6,665 reported in 2019. Among dermatology clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,559 payments — averaging $130.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$92K
- AbbVie$38K
- Pfizer$22K
- E.r. Squibb & Sons, L.L.C.$7K
- UCB, Inc.$7K
- Incyte Corporation$5K
- plus $32K from 30 others
What the payments were for
- Consulting fees$15,7458%
- Speaking & faculty fees$127,31763%
- Travel & lodging$7,0973%
- Food & beverage$51,67425%
- Education$1,3111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 102 | $91,959 |
| AbbVie | 276 | $37,908 |
| Pfizer | 78 | $22,376 |
| E.r. Squibb & Sons, L.L.C. | 37 | $7,460 |
| UCB, Inc. | 140 | $6,577 |
| Incyte Corporation | 36 | $5,150 |
| LEO Pharma Inc. | 193 | $4,045 |
| Sanofi | 89 | $3,537 |
| Amgen | 96 | $3,288 |
| Novartis | 82 | $3,191 |
| Johnson & Johnson | 99 | $2,659 |
| Sun Pharmaceutical Industries Inc. | 58 | $2,583 |
| Dermavant Sciences, Inc. | 21 | $2,264 |
| Lilly USA, LLC | 67 | $1,978 |
| Arcutis Biotherapeutics, Inc. | 67 | $1,700 |
| Botanix SB Inc | 1 | $1,150 |
| Sanofi-aventis U.S. LLC | 12 | $989 |
| Janssen Scientific Affairs, LLC | 10 | $842 |
| Regeneron Healthcare Solutions, Inc. | 18 | $820 |
| Bristol Myers Squibb | 28 | $568 |
| Organon | 13 | $527 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $400 |
| VYNE Pharmaceuticals Inc. | 6 | $216 |
| Boehringer Ingelheim | 2 | $186 |
| Mayne Pharma Commercial LLC | 5 | $137 |
| Almirall LLC | 1 | $131 |
| Genentech USA, Inc. | 5 | $125 |
| Eli Lilly | 1 | $90 |
| Helsinn Therapeutics (U.S.), Inc. | 7 | $89 |
| Regeneron | 2 | $68 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $40 |
| DUSA Pharmaceuticals, Inc. | 1 | $24 |
| Biofrontera Inc. | 1 | $19 |
| Organogenesis Inc. | 1 | $18 |
| Strata Skin Sciences, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$203,143 in reported general payments places this provider in the 95th percentile of 75 dermatology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 130 | $513,893 |
| Dupixent SyringeDupilumab | 66 | $259,741 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $88,726 |
| OtezlaApremilast | 14 | $66,506 |
| Clobetasol Propionate | 171 | $7,053 |
| Ketoconazole | 229 | $3,325 |
| Doxycycline Monohydrate | 121 | $3,110 |
| Clindamycin Phosphate | 54 | $2,991 |
| Betamethasone Dipropionate | 89 | $2,874 |
| Halobetasol Propionate | 47 | $2,069 |
| Metronidazole | 47 | $1,899 |
| Triamcinolone Acetonide | 226 | $1,847 |
| Tacrolimus | 14 | $1,299 |
| Pentoxifylline | 19 | $1,253 |
| Tretinoin | 17 | $1,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $3,288 | $66,50614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 dermatology providers in New Hampshire.
Other dermatology in Nashua
- Robert PosnickNashua$951K
- Michael LichterNashua$53K
- Christopher MancusoNashua$22K
- Stephen MoyerNashua$3K
- Rana AbdatNashua$720
- Abdulaziz AlomranNashua$369
- Elizabeth LesterNashua$78
- Abel JarellPortsmouth$2.3M
- Yulianna RussakLebanon$170K
- Peter JenkinManchester$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.